European equities traded in the US as American depositary receipts were slightly lower late Monday morning, edging 0.1% lower to 1,610.86 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and pharmaceutical company Ascendis Pharma (ASND), which climbed 7.5% and 7.2%, respectively. They were followed by biopharmaceutical companies DBV Technologies (DBVT) and Genfit (GNFT), which advanced 5.4% and 3.5%, respectively.

The decliners from continental Europe were led by software firm SAP (SAP) and lender Banco Santander (SAN), which fell 1.9% each. They were followed by brewing company Anheuser-Busch InBev (BUD) and health technology company Philips (PHG), which were down 1.6% and 1.4%, respectively.

From the UK and Ireland, the gainers were led by communications company WPP (WPP) and biopharmaceutical company Mereo BioPharma Group (MREO), which rose 11% and 2.5%, respectively. They were followed by biopharmaceutical company Bicycle Therapeutics (BCYC) and pharmaceutical company GSK (GSK), which were up 2.3% and 0.9%, respectively.

The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which dropped 6.6% and 3.8%, respectively. They were followed by biopharmaceutical companies Akari Therapeutics (AKTX) and NuCana (NCNA), which lost 3.4% and 2.6%, respectively.